Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 2, 2002, Pages 415-421

  Meehan, Kenneth R ^a   Slack, Rebecca ^a   Gehan, Edmund ^a   Herscowitz, Herbert B ^a   Areman, Ellen M ^a   Ebadi, Mark ^a   Cairo, Mitchell S ^a   Lippman, Marc E ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; CD34 ANTIGEN;

ADULT; APHERESIS; ARTICLE; BREAST CANCER; BURST FORMING UNIT E; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CLONOGENESIS; COLONY FORMING UNIT; DRUG MEGADOSE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; BREAST TUMOR; DRUG COMBINATION; GRAFT SURVIVAL; METHODOLOGY; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS;

ADULT; ANTIGENS, CD34; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; PACLITAXEL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS;

EID: 0036223616     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581602753658600     Document Type: Article

References (40)

1. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
2. Release of tumor cells from bone marrow
3. + cells mobilized by cyclophosphamide and granulocyte colony stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF
4. Mobilization of peripheral blood pregenitor cells by chemotherapy and granulocyte-macrophage colony stimulating factor for hematologic support after high-dose intensification for breast cancer
5. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF
6. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
7. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor for peripheral blood progenitor cell mobilization to growth factor alone for hematopoietic rescue after high dose chemotherapy
8. Dose escalation of paclitaxel with high dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses
9. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with ovarian cancer
10. Effect of different chemotherapy regimens on peripheralblood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor
11. Paclitaxel with rhG-CSF is an effective regimen for stem cell mobilization in breast cancer patients
12. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
13. Paclitaxel versus cyclophosphamide in peripheral blood stem cell mobilization: Comparative studies in a murine model
14. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effects
15. + cell determination by flow cytometry
16. Interleukin-2 activated hematopoietic stem cell transplantation for breast cancer: Investigations of dose levels with clinical correlates
17. Immunotherapy with Interleukin-2 and alpha-interferon following IL-2 activated hematopoietic stem cell transplantation for breast cancer
18. A Phase III multicenter randomized trial comparing cyclophosphamide, thiotepa and carboplatin (STAMP V) with or without IL-2 activated peripheral blood stem cell (PBSC) transplantation and parenteral IL-2 for high-risk breast cancer patients
19. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26
20. Cytotoxic studies of paclitaxel in human tumor cell lines
21. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
22. Taxol-mediated changes in fibrosarcoma-induced immune cell function: Modulation of antitumor activities
23. Taxol provides a second signal for murine macrophage tumoricidal activity
24. p53-independent apoptosis induced by paclitaxel through an indirect mechanism
25. Taxol, a microtubule-stabilizing anti-neoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production
26. Taxol pretreatment of tumor targets amplifies natural killer cell mediated lysis
27. High dose cyclophosphamide or etoposide as mobilization chemotherapy for peripheral blood stem cell harvest
28. CD34 content of peripheral blood progenitor cells (PBPC) is the single most powerful predictor of recovery kinetics in patients receiving myeloablative high-dose chemotherapy and PBPC infusion
29. + peripheral blood progenitor cells in patients with responding metastatic breast cancer undergoing high dose chemotherapy
30. Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer
31. Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy
32. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer
33. Enhancement of tumor cell-directed cytotoxicity and purging by activation of human peripheral blood stem cells with combination cytokines
34. Highdose chemotherapy with autolgous hematopoietic stem cell transplantation for aggressive non-Hodgkin's lymphoma
35. When to harvest peripheral blood stem cells after mobilization therapy: Prediction of CD34 positive cell yield by preceding day CD34 positive concentration in peripheral blood
36. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
37. + cell dose on resource utilization in patients after high-dose chemotherapy with peripheral blood stem cell support
38. High CD34 cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
39. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells
40. Optimization of peripheral blood CD 34 levels and routine high volume pheresis